Recent technological advances are fueling the development of cutting-edge technologies that can monitor and control physiological processes with high precision. These include devices that could ...
No currently available treatment is able to generate new contractile tissue or significantly improve cardiac function after myocardial infarction (MI), a leading cause of morbidity and mortality ...
Lonza has added new solutions to its TheraPEAK® portfolio, introducing AmpliCell® Cytokines and 293-GT® Medium to support ...